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Peer review in radiotherapy is an essential step in clinical quality assurance to avoid planning-related errors that can impact on patient safety and treatment
outcomes. Despite recommendations that radiotherapy centres should include peer review in their regular quality assurance pathway, adoption of the practice
has not been universal, and to date there have been no formal guidelines set out to standardise the process. We undertook a systematic review of the literature
to determine existing practice in radiotherapy peer review internationally, with respect to meeting structure and processes, in order to define a standardised
framework. A PubMed and Web of Science search identified 17 articles detailing peer review practice. The results revealed significant variation in peer review
processes between institutions, and a lack of consensus on documentation and reporting. Variations in the grading of outcomes of peer review were also noted.
Taking into account the results of this review, a framework for standardising the process and outcome documentation for peer review has been developed. This
can be utilised by radiotherapy centres introducing or updating peer review practice, and can facilitate meaningful evaluation of the clinical impact of peer
review in the future.
 2021 The Royal College of Radiologists. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/
by/4.0/).
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Sources of Information
A systematic review was carried out on 21 February 2019
using PubMed and Web of Science databases from 1 January
1990 to 31 December 2018, following PRISMA guidance. The
initial searchproduced2631articles.Aftera reviewof titles and
abstracts,105 articles were chosen for further review. Of these,
17 full-text articles were selected for inclusion. Reference lists
for included articles were also searched manually (no further
studies were identified for inclusion by this method).Introduction
The delivery of safe, effective radiotherapy requires
rigorous quality assurance at every step of the workflowAuthor for correspondence: P.J. Lewis, Department of Cancer Epidemiology,
Wing, Guy's Hospital, London, SE1 9RT, UK.
E-mail address: pippa.lewis@kcl.ac.uk (P.J. Lewis).
https://doi.org/10.1016/j.clon.2020.10.017
0936-6555/ 2021 The Royal College of Radiologists. Published by Elsevier Ltd. Th
org/licenses/by/4.0/).pathway. Peer review in radiotherapy is defined by The
Royal College of Radiologists as ‘a formal review by another
expert of the delineated contours used to produce a radio-
therapy plan. Reviewing target volumes also implies a re-
view of dose and fractionation’ [1]. Target volume
delineation (TVD), a major component of the radiotherapy
workflow, is a nuanced and complex task, and inter-
operator variability is well recognised [2]. Reasons for this
variability may include differing levels of experience with
particular tumour sites, seniority in post, individual stylistic
conventions and use of different protocols between centres.
Although this variation can never be completely eradicated
e given that each volume delineated requires clinical
judgement (e.g. incorporating clinical examination findings
into planning volumes for head and neck cancer)eworking
towards standardisation of approaches to the task is
desirable.Population & Global Health, King's College London, 3rd Floor, Bermondsey
is is an open access article under the CC BY license (http://creativecommons.
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histograms and other plan parameters is also often under-
taken alongside TVD review during quality assurance pro-
cesses, so that the final treatment plan has been thoroughly
assessed and agreed upon by the multidisciplinary team.
While TVD is usually a single user process, plan production
and treatment delivery and verification are often under-
taken with second check systems, or by physicists and
radiographers working in pairs. Particular emphasis on peer
review of the TVD process is thus essential in the quality
assurance pathway.
Reviews of radiotherapy protocol compliance as part of
clinical trial quality assurance have shown a significant
negative impact on overall survival and locoregional disease
control where deviations from the protocol occurred [3e5].
Protocol deviations observed included the geographical
miss of primary tumours, inadequate margins applied to
treatment volumes and partial treatment of elective vol-
umes [6]. A recent review by Cox et al. [7] of TVD assess-
ment as part of radiation therapy quality assurance (RTQA)
for clinical trials proposed a new approach to RTQA. They
recommended prospective TVD reviews for novel or com-
plex techniques and consistent reporting of RTQA pro-
gramme outcomes to enable an assessment of the impact of
TVD deviations on clinical outcomes. In the non-trial
setting, the Belgian initiative PROCARE (PROject on CAn-
cer of the Rectum) has also shown that the quality assur-
ance process improves uniformity of volume delineation
[8]. Additionally, the World Health Organisation's ‘Radio-
therapy risk profile’, published in 2008 [9], the American
Society for Radiation Oncology's White Paper in 2013 [10]
and The Royal College of Radiologists' ‘Radiotherapy target
volume definition and peer review guidance’ in 2017 [1]
have all acknowledged the benefits of peer review as a
routine quality assurance tool.
Despite these publications, there are no consensus
recommendations for a standardised peer review
meeting structure for centres undertaking the process,
and no internationally agreed minimum dataset re-
quirements for reporting peer review outcomes to
enable international benchmarking and meaningful
evaluation of its impact.
A systematic review in 2017 by Brunskill et al. [11]
evaluated the published data on peer review practice with a
focus on its clinical impact. The review found that, on
average, amendments to treatment plans were recom-
mended in 10.8% of cases; 1.8% of these changes were
defined as ‘major’ andmost of the modified plans required a
change in TVD. In designating a change as ‘minor’ or ‘major’,
the authors acknowledged a lack of standardised nomen-
clature for the recommendations. This review, together
with a further review by Huo et al. [12], also noted wide
variation in rates of plan amendment recommendations
between centres, and suggested that this heterogeneity
may relate, in part, to a lack of standardised practice in peer
review.
A recommended meeting framework and defined
outcome measures can facilitate the introduction of
formalised peer review into regular practice, and, wherepeer review is already taking place, can align these
quality improvement practices nationally and
internationally.
This review therefore seeks to carry out a comprehensive
appraisal of the literature to identify the structure and
processes of peer review meetings that are taking place
currently in radiotherapy centres internationally. It is ex-
pected to:
 Identify existing practice in peer review in radio-
therapy institutions and describe core aspects of peer
review structure
 Inform minimum criteria for peer review structure
for any centre (whether introducing or updating a
peer review programme) to allowmeaningful impact
on radiotherapy quality.
Evaluation of the clinical impact of peer review is outside
the scope of this study; and indeed has previously been
addressed in the abovementioned articles [11,12].Materials and Methods
A systematic reviewwas carried out on 21 February 2019
using PubMed andWeb of Science databases from 1 January
1990 to 31 December 2018, following PRISMA guidance
[13]. The full search strategy is available in the supple-
mentary data (Appendix A). The initial search produced
2631 articles. After a review of titles and abstracts, 105 ar-
ticles were chosen for further review. Of these, 17 full-text
articles were selected for inclusion (see Figure 1). Refer-
ence lists for included articles were also searched manually
(no further studies were identified for inclusion by this
method).
Inclusion Criteria
Published full-text articles describing peer review
meeting structure and processes in radiotherapy in-
stitutions were considered for inclusion. Articles must have
been published in English in a peer reviewed journal be-
tween the dates specified above.
Exclusion Criteria
Any papers not describing the standard practice of
radiotherapy peer review in the institution or those
describing implementation of change in the peer review
process without full details of their existing practice, were
excluded.
Publications describing peer review or quality assurance
related to clinical trials were excluded, as radiotherapy
clinical trial protocols contain specific quality assurance
instructions for institutions partaking in these studies,
which are centrally defined and may differ from local
quality assurance or peer review processes. Review articles,
surveys, abstracts and conference proceedings were also
excluded.
Fig 1. PRISMA flow chart of identification of articles for inclusion.
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PJL carried out the initial search and selected articles
meeting inclusion criteria from titles and abstracts for full-
text review. PJL and AA then independently reviewed full-
text articles to consider whether inclusion and/or exclu-
sion criteria were met.
Data Extraction
PJL extracted data from included studies, with consul-
tation from AA. Data extracted included:
 location of study;
 frequency and length of peer review meeting;
 meeting format (face-to-face, tele- or video-
conferencing);
 whether peer review was prospective or retrospec-
tive (i.e. peer review occurring before or after patient
started treatment); number of cases discussed (i.e. all cases or a random
selection);
 attendees at meetings;
 type of peer review (whether TVD only, or review of
TVD and dosimetry);
 grading system used to score recommendations of
peer review;
 standard protocol used for peer review decision-
making;
 documentation of peer review outcomes;
 feedback mechanism for sharing peer review
decisions.Results
In total, 17 articles were included in the analysis [14e30].
Table 1 is a summary of these articles describing peer re-
view meeting structure and processes. Of the 17 articles,
most were from centres in the USA (n ¼ 10, 58.8%)
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17.6%) [19,23,24]; the UK (n ¼ 3, 17.6%) [17,22,28] and
Australia (n ¼ 1, 5.5%) [16].
Eight institutions (47.1%) held weekly peer review
meetings [17e19,23,24,27,28,30], with a smaller number
meeting more frequently than this e two groups met daily
[21,25]. One centre reported their practice of ‘on-demand’
peer review, to avoid causing delays [22]. Nine (52.9%)
centres did not report the length of the meetings; of those
that did, a scheduled 1-hmeeting wasmost common (n¼ 6,
35.3%) [14,16,17,23,24,28].
Face-to-face meetings within the department were the
most common format. For 12 centres (70.6%) [17e26,28,29],
attendees were from a single institution, whereas one
article reported attendees from separate affiliated centres
[30]. Four centres (23.5%) used tele-conferencing, video-
conferencing or desktop sharing facilities to carry out multi-
institution peer review [14e17,27]. Two centres (11.8%)
carried out peer review in the presence of patients, to allow
for physical examination [20,29].
Seven centres (41.2%) carried out tumour site-specific
peer review [18,20,22,24,28e30], and were specifically
described for lung, head and neck, and breast cancers. One
report focused on peer review for stereotactic body radio-
therapy only [25]. However, this centre does carry out peer
review for all radiotherapy treatments routinely.
The criteria for inclusion of cases at peer review meet-
ings were locally defined and varied e examples included
‘all radical treatments’; ‘“complex” treatments’; ‘treatments
giving >10 Gy’; and ‘curative and complex palliative treat-
ments’. In 15 of the 17 centres, all eligible cases meeting
those criteria were discussed (88.2%) [14,15,17e22,24e30].
However, in the remaining two centres (11.8%), a random
selection from the cases eligible for discussion was chosen
[16,23].
Senior physicians (consultants or attendings) were pre-
sent at peer review meetings in all centres. Junior doctors
(registrars or residents) attended in more than half of the
centres included in this review (n ¼ 11, 64.7%)
[14,16e19,21,24,25,27,28,30]. After senior doctors, the most
commonly present staff were physicists (present at meet-
ings in 13 centres; 76.5%); dosimetrists (n ¼ 9, 52.9%); ra-
diation therapists (n¼ 7, 41%) and radiologists (n¼ 2,11.8%).
Two centres invited site-specific radiologists to themeeting,
one centre had nurses present at the meeting [21], another
invited physician assistants [27].
In most centres (n ¼ 10, 58.8%) [14e16,19,23,24,26e29],
peer review was designed to review both TVD and physics
plan evaluation. At the remaining meetings (n ¼ 7, 41.2%)
[17,18,20e22,25,30], peer review was carried out before
physics planning, and focused on TVD and organ at risk
delineation only.
Analysing TVD and physics plan characteristics at peer
review requires outcome measures to be defined. Six of 17
(35.3%) centres in this review used the following nomen-
clature ‘major change’; ‘minor change’; ‘no change’ to
determine the outcome of the peer review discussion
[14,17,20,26,27,29]. Six centres (35.3%) used their own
bespoke system [15,16,18,21,22,25], with varying levels ofdetail regarding the recommended changes (see Table 2).
Three centres simply recorded ‘change’ or ‘no change’
(17.7%) [19,28,30], whereas the ‘ABC’ system introduced by
Lefresne et al. [23] was used by two centres (11.8%) [23,24].
(In this system, a grade A is designated ‘adequate’; grade B is
defined as ‘potential changes for future are suggested,
treatment can proceed’ and grade C designates that the plan
is ‘unsatisfactory, requires change before the next
treatment’.)
Documentation of the outcome of the peer review process
was reported by 12/17 centres (70.6%) [15,16,18,19,21e26,
28,30]. Of these, 10 (58.8%) used electronic databases
[16,18,19,21e23,25,26,28,30] and two (11.8%) used written or
dictated notes [15,24]. One centre used e-mail to notify col-
leagues of changes theywould recommend (if any) after peer
review [22].
The method of feedback of peer review outcomes varied
between centres. In nine centres the recommended changes
to contours, volumes or plans were made in real time
[14,18,20,22,24e27,29]. There was no predominant pattern
of practice to ensure that changes made were documented.
In just under half of all centres (n ¼ 8, 47.1%), there was
no record made of whether revised volumes or plans were
brought back to peer review for further discussion
[15,17,19,23,24,26e28]. Of those that reported this, two
centres confirmed that all plan revisions were subsequently
re-reviewed (11.8%) [14,21]; whereas six centres (35.3%)
specifically stated that they did not bring these cases back
for further peer review after amendments were made
[16,18,20,22,25,29].Discussion
Comprehensive clinical quality assurance in radio-
therapy is key to driving progressive improvements in
treatment accuracy and patient safety. Although the
concept of peer review in radiotherapy planning is not new,
to date there has been no specific guidance or suggested
framework for setting up or improving peer review struc-
ture, nor any template or minimum dataset recommenda-
tion for publishing peer review outcomes. This systematic
review emphasises the degree of heterogeneity in practice,
and the lack of a standardised approach to quantifying the
magnitude of deviations from a recommended acceptable
treatment plan, which prevents useful analysis of peer re-
view relating to patient outcomes.
Our systematic review focused on peer review of TVD
and physics plans in the non-trial setting, yet its findings
align with those of Cox et al. [7], which addressed quality
assurance in radiotherapy clinical trials.
Standardised, evidence-based RTQA procedures for
clinical trials are championed by the Global Quality Assur-
ance of Radiation Therapy Clinical Trials Harmonisation
Group, but as noted by Cox et al. [7], these procedures tend
to focus on prescriptions, dosimetry or other technical
planning issues, rather than TVD accuracy. Their review
recommends incorporation of a new approach to TVD
quality assurance as part of radiotherapy clinical trial
Table 1
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clinical outcomes, and accelerate the evidence base for the
best RTQA approach to TVD assessment.
The recommendations from our systematic review
incorporate a standardised framework for both TVD and
physics plan peer review, and thus can contribute to the
harmonisation of quality assurance approaches in both
clinical trials and standard practice.
In the subsequent discussion we highlight the main
findings of the review and propose guidance for peer review
processes and outcome documentation.
Frequency and Length of Peer Review Meetings
The review found that most centres held weekly meet-
ings. Two centres [21,25] held daily meetings, but this is
unlikely to be feasible for most. Indeed, one centre's expe-
rience of ‘on-demand’ peer review came about precisely
because even once-weeklymeetingswere becoming difficult
to maintain, due to workload and time constraints [22]. Ingeneral, a scheduled peer reviewmeeting at a regular time is
conducive to efficient and consistent quality assurance, by
facilitating the regular attendance of key teammembers and
encouraging the acceptance of peer review into routine
practice. In larger centres with a high volume of patients,
sub-specialised peer review meetings, for discussion of
tumour site-specific cases, may be necessary, enabling mul-
tiple weekly meetings with tumour site-specialist clinicians.
The ideal length of a peer review meeting is a question
for each individual centre, dependent upon their caseload
and meeting infrastructure. In a survey of American in-
stitutions undertaking peer review in 2012, it was found
that, on average, 2.7 min of discussionwas required for each
case [31]. Mitchell et al. [26] found that cases were dis-
cussed for, on average, 7 min, with variations observed
depending on whether changes were required or not (11.8
versus 6.7 min). Albert et al.’s [14] analysis found that the
mean presentation timewas 8min, with a caseload of about
six to seven new patients for discussion per week. Taking
the average durations of case discussion as 10 min for a case
Table 3
Definitions of major and minor changes recommended at peer
review
Major change Change that would affect the likelihood of
cure or locoregional disease control
Change requiring editing of a contour (GTV
or CTV) by more than 1 cm in any direction,
or to prevent geographical miss of target
Change to plan required to achieve pre-
specified dosimetric parameters for target
volume and OAR/DVH constraints
Change in dose or number of fractions
Change in treatment modality
Minor change Change that would not affect the likelihood
of cure or locoregional disease control
Change requiring editing of a contour by less
than 1 cm
CTV, clinical target volume; DVH, dose volume histogram; GTV,
gross tumour volume; OAR, organ at risk.
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change or a minor change, as per Mitchell et al.’s [26] esti-
mates, we could realistically expect between eight and 10
cases to be discussed in an hour long meeting. Individual
radiotherapy centres should clearly categorise which cases
should routinely undergo peer review, taking into account
their caseload and expected case complexity, in order that
sufficient time is allocated to case discussion.
Format
In settings where radiotherapy treatment is delivered
across a network of centres, tele-conferencing and video-
conferencing are becoming routine practice to connect col-
leagues in separate locations. There are increasingly sophis-
ticated technologies emerging to allow fast, confidential
transfer of clinical information between colleagues working
in different locations. Adoption of these technologies (e.g.
cloud-based technology [32]) cannot only improve efficiency
and save travel-time, but canalso facilitate offlinepeer review
and provision of detailed remote feedback. Such technologies
also provide an opportunity for cross-border peer review for
countries developing their radiotherapy infrastructure while
facing workforce shortages.
Attendees
Peer review relies upon feedback from ‘non-treating’
colleagues, i.e. those who are not the patient's named
clinician. Peer review meetings should therefore mandate
the presence of at least one non-treating physician with
expertise in the tumour site sub-specialty, in order to
provide objective feedback on treatment planning. When
analysing target volume contours alone, although gener-
ally a clinician-led task, the presence of physics, radiation
therapy and dosimetry staff can encourage holistic feed-
back. As shown in various reports [14,15,17], peer review
discussions provide a rich educational environment, and
over time, rates of plan amendment following peer review
can be seen to reduce, reflecting a ‘learning curve’ [11,25].
In light of this, attendance at peer review should be
actively encouraged for students and trainees of all
disciplines.
Case Inclusion
The discussion of all new radiotherapy cases presenting
for treatment is desirable. However, as discussed above,
time constraints canmake this difficult to achieve. Brammer
et al. [17] reviewed all cases (other than two-field tangential
breast treatments not involved in a clinical trial) that were
longer than five fractions. The inclusion of high frequency/
low complexity plans (e.g. breast and simple prostate plans)
may cause meetings to run over time, and with low rates of
plan amendments, it may be more pragmatic to include a
random selection of these rather than discussing each one.
Pham et al. [27] described inclusion of any complex case
(including palliative cases) selected by the treating physi-
cian or resident who would like to seek opinions from his/her colleagues to ensure the best treatment decision for the
patient. For high throughput centres, multiple peer review
meetings, dedicated to specific tumour sub-sites, may be
necessary to allow thorough discussion of all eligible cases.
For smaller centres, it may be sufficient to carry out a single
meeting for all cases, or, for example, to hold separate
‘radical’ and ‘palliative’ meetings. Categorisation of peer
review need per pathology or treatment intent should be
agreed locally and reviewed regularly.
Time Point for Peer Review in Planning Pathway
Most cases (n ¼ 13, 76.5%), were discussed prospectively,
i.e. before the first fraction of treatment was given. Retro-
spective peer review can be beneficial, particularly as an
educational tool, and where modifications are not expected
to necessitate re-planning. Prospective peer review is rec-
ommended by the Royal College of Radiologists [1], and is
supported by the results from this review.
For complex treatments, for example head and neck,
skull base or stereotactic radiotherapy, a review of target
volumes prior to physics planning can prevent the need for
time-consuming re-planning if a treatment volume requires
amendment.
More than half of the reports included here used peer
review sessions to analyse both TVD and plan parameters
such as dose-volume histograms, objectives and con-
straints, and dose homogeneity, at the same time. Pham
et al. [27] and Rosenthal et al. [29] concluded that due to a
high number of changes recommended at peer review for
complex treatments, such as head and neck, peer review is
best carried out prior to physics input to make changes
easier to implement. Mackenzie et al. [33] also detailed their
processes for peer review of head and neck cases prior to
physics planning (in contrast to breast and lung peer re-
view, where TVD and physics plans were reviewed
together). They also concluded that peer review for complex
cases is more efficient when carried out prior to physics
and/or dosimetric planning.
P.J. Lewis et al. / Clinical Oncology 33 (2021) 248e260258We recommend therefore that peer review for simpler
cases can be carried out for TVD and plan review after
physics/dosimetry input, and for more complex cases, peer
review should focus on TVD alone to ensure agreement on
treatment volumes before planning begins.Guidelines and Protocols
All centres delivering radiotherapy should have protocols
outlining instructions for TVD, organ at risk definition, dose
fractionation schedules and normal tissue constraints for
each tumour subtype. Clinicians often also use open access
contouring atlases and radiotherapy guidelines from clinical
trial protocols to assist with treatment planning. Almost
30% of institutions in this review did not document theTable 4
Recommendations for peer review structure
Frequency At least once weekly
Length At least 1 h e allowing approximately 8e10 case
If larger centres are seeing more than 10 new cas
 holding tumour site-specific meetings to ensur
Timing Prospective peer review, i.e. before first fraction o
treatment would be delayed.
It is recommended that peer review for complex
(ii) Plan review, where physics/dosimetry inpu
For less complex cases, where peer review takes place a
both contours and plan parameters.
Format If discussing cases from multiple centres, video-c
If video-conferencing is not available, representat
Attendees Physicians, physicists, dosimetrists, radiation ther
For educational purposes it is recommended that
If feasible, attendance of radiologists can be bene
Case inclusion All radical/curative intent cases should be discuss
Once the peer review process has been running fo
results of audits can inform whether all cases nee
inclusion could be reduced to a selection of cases
Individual centres should agree on categorisation
complexity.
Any cases (including palliative cases) that are requ
Standard Each centre should develop local institutional rad
peer review decisions are made, utilising nationa
Clinical trial protocols can also be used to aid TVD
Discussion points The following points should be the minimum dat
 Diagnosis and staging (TNM)
 Treatment intent
 Prescribed dose/fractionation
 GTV/CTVs/PTVs/OARs e review of contours
 Review of plan parameters
 Has the recommended change been carried ou




Document outcome of peer review using major/m
Use standardised template to document all aspec
(see supplementary data for example)
CTV, clinical target volume; GTV, gross tumour volume; OAR, organ atguidelines used to make decisions at peer review, and a
further 23% relied upon consensus between attendees.
When critically appraising target volume definition within
the peer review setting, it is recommended that centres
determine the standard guideline or protocol against which
each case is being compared e this also helps to ensure that
centres maintain up to date knowledge of recent de-
velopments in contouring recommendations.Grading Systems
Table 2 shows the variation in definitions or outcome
measures applied at peer review. No consensus exists, but
as an outcome of this review and having collated the evi-
dence from international practice, we propose that centress for discussion.
es for radiotherapy per week, consider:  holding more than one
peer review meeting
per week
e no more than 10 cases/h are scheduled.
f treatment, is recommended in all cases except where urgent
cases takes place in two stages: (i) TVD peer review prior to
physics/dosimetry input, to
avoid re-planning in the
event of a major change;
followed by
t is reviewed.
fter physics/dosimetry planning, the review should include assessment of
onferencing  screen-sharing should be used.
ives from each centre should attend in person.
apists, students and administrative staff should all attend.
students and trainees of all disciplines are encouraged to attend.
ficial.
ed.
r sufficient time to audit local outcomes (i.e. rate of plan change),
d to be discussed (e.g. if rate of major change is less than 2%,
to increase meeting efficiency).
for case inclusion at peer review, according to caseload and
ested for review by the treating physician should also be included.
iotherapy guidelines or protocols as the standard against which
l/international guidelines (such as online contouring atlases).
and inform local guideline development.
aset recorded:
t in real time and subsequently agreed?
her peer review of amendments?
inor criteria (see Table 3).
ts of peer review
risk; PTV, planning target volume; TVD, target volume delineation.
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system for all recommendations, for ease of audit and
comparison within and between institutions. Taking into
account the definitions set out in Table 2, alongside guid-
ance from The Royal College of Radiologists [1], we have
made a number of suggestions (see Table 3).
Documentation of Outcomes
From the results of this review, it is clear that there is a lack
of consistency inhowpeer reviewoutcomesaredocumented,
and a lack of documentation within centres regarding
whether the recommended changes are actually carried out.
The impact of peer review recommendations cannot reliably
be reported if it is not clear that they have been implemented,
therefore it is recommended that all centres document the
specific changes recommended at peer review, and record
whether these recommendations have been implemented.
Toohey et al. [34] published their updated RANZCR peer
review audit instrument in 2006, which provides a highly
structured framework for auditing all aspects of radio-
therapy practice, not limited to the peer review process.
Although within this framework there is a template for
documenting peer review outcomes (consisting of six
‘performance criteria’ including target volume coverage,
critical structure doses, prescribed total dose for each vol-
ume and fractionation schedule), the tool is used for a more
wide-ranging audit process and, thus, is not designed to be
a peer review-specific documentation framework. Building
upon the guidance set out in The Royal College of Radiolo-
gists' peer review document [1], a suggested template for
peer review case discussion documentation can be found in
the supplementary data (Appendix A).
Recommendations for Peer Review Processes
Table 4 summarises the commonalities across interna-
tional peer review processes, but also takes into account
guidelines for peer review by national/international profes-
sional bodies [1,9,10]. It is a pragmatic, evidence-based tool
that should be considered for use as a streamlined, stand-
ardised approach to undertaking and reporting peer review.
Conclusion
Significant variation exists in peer review practice among
radiation oncology institutions, and heterogeneity in out-
comes may relate to this lack of harmonised practice. In
order to allow meaningful evaluation of the impact of peer
review on clinical outcomes, standardisation of peer review
practice is recommended, and should be facilitated by the
implementation of guidelines and protocols. This review
highlights the variations in practice and suggests critical
elements that contribute to effective and efficient peer re-
view. A framework for undertaking peer review, including a
standardised grading system for peer review outcomes and
a suggested template for documenting the proceedings, has
been designed on the basis of these findings. It can be uti-
lised by radiotherapy centres introducing or updating peerreview practice and can facilitate meaningful evaluation of
the clinical impact of peer review in the future.Conflicts of Interest
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